Upcoming Webinars
January 26, 2022
10:00AM EST| 3:00PM GMT | 4:00PM CET
Most Recent
Jan 2022
This webinar will be useful for researchers, regulators, academics, industry sponsors, and instrument developers in the clinical outcomes assessment (COA) field working on the development, evaluation, and implementation of performance outcome (PerfO) measures for use in capturing clinical benefits in treatment trials for medical label claims.
Jan 2022
This webinar emerges in the sequence of relevant topics highlighted in the ISPOR Science Strategy (particularly the Special Populations and Technologies and Health Economics, Access and Policy sections) and the Special Interest Group on biosimilars, by specifically reflecting on how to tackle inefficiencies of healthcare systems in the future with biosimilars.
Nov 2021
Consider payer decision making in the context of health preference research (HPR) in market access and health technology assessment (HTA). How does it fit together? What are the differences between patient preferences and public preferences as they apply to HTA? This webinar will provide a basic introduction to these issues and more.
Sponsored by Happy Life Technology
Oct 2021
There is increasing demand for real-world evidence (RWE) in healthcare decision making around the global, same as in China. Being the world’s second-largest market (after the US) and the only major market growing in the high single-digits annually, the regulatory and market access environment is evolving rapidly amid the fast development of healthcare sector in China.
Sep 2021
During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.
Sponsored by Syneos Health
Sep 2021
In this webinar, experts will explore embedded clinical trials and their potential for effectively generating real world evidence, and review case studies illustrating best practice for these trials in action.
Economic Evaluation
Sponsored by FIFARMA
Apr 2021
Esta sesión, va a explorar modelos potenciales para generar inversiones a corto plazo para la atención en salud en América Latina, ya sea de nuevas fuentes de ingresos, opciones de financiación internacional o, inversionistas del sector privado. Incluiremos experiencias de países de América Latina así como modelos que se han mostrado prometedores en otros contextos, sectores o regiones que pueden contener lecciones aprendidas relevantes.
Feb 2021
In this webinar, expert speakers will explore the current digital healthcare landscape in Asia Pacific including regulatory, value assessment and reimbursement aspects, as well as future directions. Experiences with validation, evidence generation and reimbursement pathways for digital health solutions will be also shared through case studies.
Feb 2021
This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.
Dec 2020
This webinar will discuss the rationale for the revision of the original Consolidated Health Economic Evaluation Reporting Standards (CHEERS) reporting guidelines and outline directions for the new reporting standards, as suggested by a Delphi survey.
Health Technology Assessment
Nov 2021
Consider payer decision making in the context of health preference research (HPR) in market access and health technology assessment (HTA). How does it fit together? What are the differences between patient preferences and public preferences as they apply to HTA? This webinar will provide a basic introduction to these issues and more.
Jul 2021
Panelists will discuss what approaches to use, describe the relevance for HTA organizations and how it might best be used, and will provide reflective thoughts on potential gaps, and where future efforts might be.
Aug 2020
In this session, experts from Latin America, Asia-Pacific and EMEA will discuss the role of HTA in UHC, including priority setting, coverage and financing, and share their experience in effective application of HTA to support designing benefits package for UHC while tackling the encountered challenges.
Apr 2020
Health technology assessment (HTA) is gaining widespread acceptance and plays a vital role in healthcare decision making in many countries across the Asia Pacific region. In order to meet the changing demands of patients in light of new health technology innovations, HTA processes have needed to adapt. In this webinar, leading HTA experts from Thailand and South Korea will provide updates on recent developments in their countries’ HTA processes to strengthen patient access to innovative health technologies.
Real-World Data & Information Systems
Sponsored by Happy Life Technology
Oct 2021
There is increasing demand for real-world evidence (RWE) in healthcare decision making around the global, same as in China. Being the world’s second-largest market (after the US) and the only major market growing in the high single-digits annually, the regulatory and market access environment is evolving rapidly amid the fast development of healthcare sector in China.
Sponsored by GenomiCare Biotechnology
Jun 2021
The potential to improve cancer care in China is clear, the journey to that destination is not. Here, we bring together a group of experienced RWE leaders, thinkers, and “doers" for an interactive, friendly, and informative discussion about the unique attributes of oncology care in China: diverse patient journeys, integration with traditional medicines, immature EHR integration across institutions, and the rapidly evolving regulatory and reimbursement environment.
Dec 2020
This session will provide updates from the initiative including progress on the study registration site and the special task force on RWE protocol templates.
Sep 2020
Certara’s extensive experience with the recently accessible French administrative healthcare database (SNDS) has provided key insights into how the database can be used for a larger impact on patient access, health technology and public health assessments
Patient-Centered Research
Jan 2022
This webinar will be useful for researchers, regulators, academics, industry sponsors, and instrument developers in the clinical outcomes assessment (COA) field working on the development, evaluation, and implementation of performance outcome (PerfO) measures for use in capturing clinical benefits in treatment trials for medical label claims.
Sep 2021
During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.
Sponsored by Medisafe
May 2021
In a healthcare world saturated with digital tools – and 40% of patients turning to digital resources – the best patient outcomes actually occur when personal, human-touch plays a notable part in acclimating patients on their prescription therapy. New research suggests that adding personal connection to digital health can increase adoption by 70%, leading to greater outcomes and faster healing.
Feb 2021
Many preference researchers have been quick to respond to this need and have conducted empirical COVID19 studies to better understand the value of health and health-related policies.
Methodical & Statistical Research
Aug 2021
This webinar is a collaboration between ISPOR’s Health Preference Research Special Interest Group and the New Professionals Network.
Feb 2021
Many preference researchers have been quick to respond to this need and have conducted empirical COVID19 studies to better understand the value of health and health-related policies.
Dec 2020
In this webinar, we will consider the apparent disconnect between HTA assessments of treatments within a specified location in a treatment sequence and clinical practice where a treatment sequence is tailored to the patient.
Health Policy & Regulatory
Jan 2022
This webinar emerges in the sequence of relevant topics highlighted in the ISPOR Science Strategy (particularly the Special Populations and Technologies and Health Economics, Access and Policy sections) and the Special Interest Group on biosimilars, by specifically reflecting on how to tackle inefficiencies of healthcare systems in the future with biosimilars.
Mar 2021
This webinar will review each of the theme areas and focal points in the Strategy, the process by which they were generated, and their potential implications for future ISPOR activities.
Mar 2021
To help viewers better understand the region, this webinar brings together a panel of health experts across Latin America to provide multiple perspectives on the effects of COVID-19 in the healthcare of Latin America including regulatory change and innovation, public-private partnerships in health, digital transformation, regional and inter-regional cooperation and capacity building. Brought to you by ISPOR's Latin America Consortium.
Sponsored by FIFARMA
Mar 2021
En este evento educativo, escucharemos a dos expertos que han estado a la vanguardia de los esfuerzos en America Latina por implementar estos acuerdos, con el fin de balancear el acceso a nuevas tecnologías con un financiamiento sostenible. Héctor Castro (Líder global en financiamiento a la salud, tecnologías, datos e impacto, MSH) y Alicia Ferreira (Ex-directora del Fondo Nacional de Recursos) compartirán con nosotros ejemplos reales de cómo los Acuerdos de Entrada Gestionada se están implementando progresivamente en América Latina y, recomendaciones sobre cómo crear las bases para un camino mejorado hacia un mayor acceso a tratamientos para todos los latinoamericanos.
Study Approaches
Oct 2020
In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.
Jun 2020
This webinar will explore why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare. Speakers will discuss formative qualitative research for the identification and generation of attributes and levels and qualitative research for testing survey comprehension and decision-making processes.
Apr 2020
This webinar will explore the value and challenges of linking administrative claims data to additional data sources in order to provide a more comprehensive look at the patient journey through a disease state. Data linkage types, techniques and best practices will be discussed.
Nov 2020
This capstone webinar culminates the ISPOR-IVI series with a reflection on future direction and commitment needed to improve the scientific credibility and relevance of VA/HTA to pandemic preparedness.
Nov 2020
COVID-19 has brought home the importance of public health expertise and investment. How should VA/HTA address risks and benefits of public health policy interventions? How do we model the interactions between health and other sectors in our economy? What are the roles of the public vs. private sector in public health infrastructure and interventions? Are there policy implications for public health investment that VA/HTA can help frame?
Oct 2020
This webinar features a range of international speakers who will introduce several One Health-related topics as they pertain to HEOR, with a view gauging interest in the formation of an ISPOR Animal and One Health Special Interest Group (SIG).
Sep 2020
Evolving data from COVID-19 tell the story we already know: the impact of this disease affects people – especially people of color - disproportionately, both in terms of risk and prevalence, as well as access to care and outcomes. In considering VA/HTA approaches, as well as in discerning how to apply such findings, how must we address questions of ethics and equity?
Sep 2021
During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.
Feb 2021
This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.
Oct 2020
The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.
Sponsored by Biogen
Feb 2021
This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.
Dec 2020
This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.
Nov 2020
This webinar will define how Alzheimer’s disease affects underserved communities; share opportunities to create more equitable, ethical, and inclusive value frameworks; and educate on the community’s role in solving this problem.
Oct 2020
This webinar seeks to explore some of these broader elements within the context of evolving value assessment and considers how they may meaningfully be incorporated to facilitate a more holistic approach to valuing medical innovation.
Need More Information or Have Questions?
Contact us for more information on ISPOR education and training.